A Randomized; Placebo-controlled; Double Blind; Trial of the Administration of the MDR Modulator; Zosuquidar Trihydrochloride (LY335979); During Conventional Induction and Post-Remission Therapy in Patients Greater than 60 Years of Age with Newly Diagnosed Acute Myeloid Leukemia; Refractory Anemia with Excess Blasts in Transformation or High-Risk Refractory Anemia with Excess Blasts